TRIKAFTA (COPACKAGED) Drug Patent Profile

Which patents cover Trikafta (copackaged), and what generic alternatives are available?

Trikafta (copackaged) is a drug marketed by Vertex Pharms Inc and is included in two NDAs. There are thirty-five patents protecting this drug.

This drug has five hundred and nineteen patent family members in forty-eight countries.

The generic ingredient in TRIKAFTA (COPACKAGED) is elexacaftor, ivacaftor, tezacaftor; ivacaftor. One supplier is listed for this compound. Additional details are available on the elexacaftor, ivacaftor, tezacaftor; ivacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Trikafta (copackaged)

Trikafta (copackaged) was eligible for patent challenges on October 21, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 8, 2037. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRIKAFTA (COPACKAGED)

International Patents:	519
US Patents:	35
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIKAFTA (COPACKAGED)
DailyMed Link:	TRIKAFTA (COPACKAGED) at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRIKAFTA (COPACKAGED)

Constraining patent/regulatory exclusivity:

11,453,655

NDA:

212273

Dosage:

TABLET, TABLET;ORAL

Constraining patent/regulatory exclusivity:

11,453,655

NDA:

217660

Dosage:

GRANULES;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for TRIKAFTA (COPACKAGED)

TRIKAFTA (COPACKAGED) is protected by eighty-nine US patents and nine FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023		RX	Yes	Yes			Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-001	Oct 21, 2019		RX	Yes	Yes			Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021		RX	Yes	No			Y	Y
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021		RX	Yes	No			Y

Expired US Patents for TRIKAFTA (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-001	Apr 26, 2023
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-001	Oct 21, 2019
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273-002	Jun 8, 2021
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660-002	Apr 26, 2023

International Patents for TRIKAFTA (COPACKAGED)

When does loss-of-exclusivity occur for TRIKAFTA (COPACKAGED)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hungary

Israel

Japan

Jordan

Lithuania

Mexico

Moldova, Republic of

Morocco

New Zealand

Peru

Portugal

San Marino

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIKAFTA (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2563778
Cyprus	1121572
Ukraine	125245	МОДУЛЯТОРИ РЕГУЛЯТОРА ТРАНСМЕМБРАННОЇ ПРОВІДНОСТІ ПРИ МУКОВІСЦИДОЗІ (MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR)
New Zealand	596889

Supplementary Protection Certificates for TRIKAFTA (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1773816	C 2015 027	Romania		PRODUCT NAME: IVACAFTOR SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIAN-(5-HIDROXI-2,4-DITERT-BUTIL-FENIL)-4-OXO-1H-CHINOLIN-3-CARBOXAMIDA SAU O SARE ACCEPTABILA FARMACEUTIC AACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/12/782/001, EU/1/12/782/002; DATE OF NATIONAL AUTHORISATION: 20120723; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/12/782/001, EU/1/12/782/002; DATE OF FIRST AUTHORISATION IN EEA: 20120723
1773816	2015/036	Ireland		PRODUCT NAME: N-(5-HYDROXYL-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE (IVACAFTOR) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120723
1773816	PA2015028	Lithuania		PRODUCT NAME: IVACAFTORUM; REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120723
2826776	C20210011 00330	Estonia		PRODUCT NAME: TESAKAFTOOR/IVAKAFTOOR;REG NO/DATE: EU/1/18/1306 06.11.2018

TRIKAFTA (copackaged) market dynamics and financial trajectory (Vertex/Cystic Fibrosis drug)

Last updated: May 15, 2026

TRIKAFTA (copackaged) is the dominant CFTR modulator in cystic fibrosis (CF) across major markets, driven by high clinical adoption in eligible genotypes and continued label expansion. Financial trajectory has been shaped by (1) category-level pricing and net-price erosion, (2) mix shifts across the eligible population, (3) competitive pressure from next-generation modulators in CF, (4) geographic and reimbursement variability, and (5) manufacturing and supply continuity constraints typical of high-demand specialty biologics-like workflows, even though TRIKAFTA is small-molecule.

What are the key market dynamics driving TRIKAFTA sales growth and erosion?

TRIKAFTA’s market dynamics follow CFTR-modulator adoption patterns: physicians prioritize genotype eligibility, payers require step-edits tied to prior therapy history, and procurement is sensitive to net-price and contracting cadence. The drug is sold as a “copackaged” regimen, which affects gross-to-net mechanics because payer formularies and contracting typically track the regimen SKU, not interchangeable components.

Which factors increase TRIKAFTA demand (eligible patients, switching, and persistence)?

• Genotype eligibility expansion within the CFTR modulator class has historically supported incremental starts. TRIKAFTA is positioned for the broadest responsive genotype coverage among the leading CFTR modulators, reducing “therapy gap” for patients previously dependent on older regimens.
• Switching dynamics: once payers and clinicians have tolerated the modulator regimen, persistence tends to improve because discontinuation risks are high. The market therefore behaves like a stable chronic therapy with modest churn.
• “Treatment acceleration” through early-line use: as guidelines and clinical practice normalize TRIKAFTA, patients move toward earlier initiation rather than reserving modulators for later-stage disease.

Which factors pressure TRIKAFTA net sales (pricing, payer restrictions, and competitive entrants)?

• Gross-to-net erosion: annual price increases and contract renewals can be offset by discounts, rebates, and outcomes-based arrangements at the payer level. This is especially material in the US where contracting is aggressive for specialty therapies.
• Indication and population saturation: once the eligible population is largely treated, growth depends on incident cases, diagnosis rate improvements, and any label broadening rather than simple share capture.
• Competitive encroachment: other CFTR modulators and combination approaches can reduce incremental switch rates, particularly for payers that prefer lower acquisition cost within the class.

How has TRIKAFTA performed financially over time (revenue trend, margins, and growth drivers)?

TRIKAFTA’s financial trajectory is best understood through Vertex’s CF-focused revenue engine. Vertex reports financial results in segments that largely reflect CF franchise performance, with TRIKAFTA as the core contributor. The trajectory has been characterized by sustained high revenue scale, then a phase of moderating growth as market penetration increases and net pricing becomes more variable.

What does the revenue mix imply about TRIKAFTA’s growth stage?

• High penetration: TRIKAFTA has moved from expansion to maturity in many high-income markets. In that stage, growth is increasingly tied to diagnosis incidence and any incremental label expansions rather than broad, untapped genotype coverage.
• International variability: CF care access, willingness-to-pay thresholds, and government reimbursement models cause uneven adoption rates, with periodic “catch-up” in new or reformed payer systems.

What are the typical financial levers visible in specialty pharma for TRIKAFTA-like products?

• Specialty payer contracting effects: net revenue growth can lag gross pricing due to contracting cadence and utilization shifts.
• Cost of goods and supply: specialty manufacturing and logistics affect operating margin. For high-demand oral regimens, supply continuity is a key determinant of avoidable revenue loss.
• Commercial spend and lifecycle management: as growth matures, Vertex can reallocate spend toward retention, access, and competitive defense rather than pure market development.

When does TRIKAFTA lose exclusivity and how does that affect valuation and revenue risk?

TRIKAFTA is subject to a layered exclusivity framework: composition-of-matter patents, formulation and method patents, and regulatory exclusivities. The practical “when” differs by geography because patent term adjustments, patent linkage, and regulatory exclusivity periods vary.

What is the real-world exclusivity risk window for TRIKAFTA?

• Revenue risk is front-loaded to the period when generic or “authorized” competitive supply becomes feasible. In the US, the leading risk pathway is Paragraph IV filings to trigger a potential 180-day exclusivity for the first challenger, coupled with settlement dynamics.
• In practice, the effective exclusivity cliff is determined by the last-to-expire relevant patent in each jurisdiction and the presence of Orange Book-listed patents covering the marketed regimen and dosing form(s).

How does “copackaged” status change exclusivity and generic entry barriers?

Copackaging typically increases barriers because challengers must address:

• regimen-level formulation and stability requirements,
• specific dosing strengths and combinations,
• device-like operational steps in the patient-facing regimen (even if not a device),
• and any patents covering the copackaged form or manufacturing method.

That often results in fewer straightforward “drop-in” generics and can shift entry from simple ANDA manufacturing to more complex design-around strategies.

What patents protect TRIKAFTA (copackaged), and how strong is the patent estate?

TRIKAFTA’s patent protection is not a single “composition patent.” It is a dense estate with multiple patent families covering the active ingredients, combinations, manufacturing, and formulation attributes. For business decisions, the key is mapping what is Orange Book-listed for the marketed drug and which patents are later in time.

How does patent strength translate into licensing leverage?

• Dense estates enable longer exclusivity in practice because ANDA filers must either (1) challenge at least one core patent successfully or (2) carve around specific formulation and method claims.
• Higher complexity increases the cost and litigation timeline, which raises the probability of settlement and delays “at-risk” entry.

What is the most likely generic entry pathway for TRIKAFTA in the US?

• ANDA route with Paragraph IV challenges to Orange Book-listed patents (where listed patents can be asserted).
• Design-around reformulation is possible but tends to be slower and more expensive when regimen-specific and formulation-specific protections exist.
• “Launch-at-risk” depends on injunction risk, court scheduling, and settlement history.

What generic entry risks exist for TRIKAFTA, and what triggers a first generic launch?

The generic entry risk is a function of: (1) the time remaining to key listed patent expirations, (2) how courts treat claim construction and validity arguments, and (3) settlement terms that commonly convert litigation into delayed launches.

What triggers the first meaningful revenue share loss?

• Patent expiration of the last critical Orange Book patent covering the marketed regimen.
• Settlement agreement that fixes a launch date, often coupled with a “no earlier than” commitment.
• Successful Paragraph IV litigation resolving at least one asserted patent such that an ANDA can proceed to market.

How copackaging influences launch timing

Copackaged products require specific release, stability, and manufacturing controls. These can slow challenger timelines even after legal clearance, especially if formulation patents and process patents remain unaddressed.

How does TRIKAFTA compare with other CFTR modulators in market dynamics and earnings impact?

Within CFTR modulators, the market share battle typically reflects:

• width of genotype coverage,
• dosing convenience,
• payer preference and net price,
• and patient outcomes that affect access.

Which competitors most influence TRIKAFTA’s pricing power?

• Alternative CFTR modulators with overlapping genotype eligibility.
• Any next-generation combination modulators that reduce cost-per-member or improve access through payer contracts.

What determines TRIKAFTA’s competitive advantage in contracting?

• Health-economic evidence that supports coverage without prolonged step edits.
• Stable long-term outcomes and low discontinuation rates.
• A payer experience that reduces perceived risk versus less-established entrants.

What is the Orange Book status of TRIKAFTA and how many patents are typically listed?

The Orange Book provides the legal linkage for US ANDA challenges via listed drug patents. The number and category mix (composition, method-of-use, formulation/process) determine challenge complexity.

What matters for “Orange Book status” in practice

• The “listed patents” that are asserted in litigation.
• Whether patents are method-of-use or formulation-specific, which typically raises design-around difficulty.
• The “last-to-expire” patent date, which sets the outer boundary for generic entry.

What FDA regulatory milestones and post-approval events shape TRIKAFTA demand?

Regulatory milestones influence demand through label expansion and access. For TRIKAFTA, market impact comes from any expansion of eligible genotypes, dosing regimens, or pediatric coverage that increases the treatable population.

Which regulatory events typically move commercial outcomes

• Label expansions that broaden eligibility.
• Supplemental approvals for pediatric populations that expand incident utilization.
• Any manufacturing or supply-related FDA actions that affect ability to meet demand.

What patent litigation affects TRIKAFTA, and how do settlements typically alter launch timelines?

Litigation is the key determinant of whether challengers launch at the earliest lawful date or later due to settlement.

How settlement dynamics affect revenue protection

• Settlements often convert uncertainty into fixed “no sooner than” launch dates.
• Some settlements include cross-licenses, royalty structures, or restrictions on certain strengths or indications.

What business professionals watch

• Court scheduling and injunction rulings, which control at-risk launch timing.
• Whether multiple patents are asserted in parallel, which impacts how far generic challenges can proceed if only one patent is invalidated.

How does geography affect TRIKAFTA sales growth (US vs. EU vs. ROW)?

TRIKAFTA’s financial trajectory varies by market due to:

• pricing regulation and health technology assessment (HTA) in EU and UK,
• reimbursement structures in ROW,
• CF incidence rates and diagnosis rates,
• and availability of specialty center prescribing pathways.

US

• Strong specialty contracting and high payer leverage can drive net price fluctuations.
• The Orange Book and Hatch-Waxman framework shapes generic entry timing risk.

EU/UK

• HTA outcomes influence reimbursement entry speed.
• National formularies determine tiering, and revisions to HTA may change net price.

Rest of World

• Patient access and pricing discipline drive adoption.
• Portfolio competition and local regulatory approval speed affect launch pacing.

What manufacturing and supply dynamics can impact TRIKAFTA revenue?

Even when patents and exclusivity hold, supply can determine quarterly sales. For a high-demand oral regimen, risks include:

• sourcing constraints for key starting materials,
• batch release timing,
• and scale-up capacity relative to peak demand.

How supply disruptions translate into financial outcomes

• Lost sales in the short term can be partially offset later, but payer commitments and patient continuity can create longer recovery.
• Delayed shipments can raise chargebacks and contract penalties depending on the payer terms.

What does TRIKAFTA’s commercial outlook imply for 12 to 36 month financial trajectory?

Near-term revenue direction depends on whether category growth remains steady versus moderating due to penetration and contracting. The most important forward-looking variables are:

• incremental eligible population growth (pediatric and any further label expansions),
• net price trajectory through annual contract renegotiations,
• competitive pressure within CFTR modulators,
• and any legal events affecting exclusivity timing.

Base-case revenue drivers

• Stable persistence in existing patients.
• Ongoing incident patient starts as diagnosis rates evolve.
• Continued payer access in key markets.

Downside revenue drivers

• Faster-than-expected net price erosion.
• Competitive switching that reduces incremental start rates.
• Litigation-driven changes that bring forward generic-or-competition milestones.

Key Takeaways

• TRIKAFTA’s market dynamics are governed by CFTR-modulator adoption, payer contracting, and penetration-driven maturity effects after broad eligible coverage.
• Financial trajectory is anchored by Vertex’s CF franchise scale, with growth increasingly influenced by net price, access, and incident starts rather than new broad genotype capture.
• “Copackaged” regimen status raises generic entry complexity by increasing design-around and formulation/process constraints for challengers.
• The most material revenue risk is the timeline of last-to-expire critical Orange Book-listed patents and any settlement-backed “no sooner than” launch dates.

FAQs

1. How does TRIKAFTA’s copackaged regimen affect ANDA formulation and stability design-around risk?
2. What is the typical payer step-edit and prior-therapy requirement that determines TRIKAFTA access in commercial plans?
3. Which CFTR modulator competitors most influence TRIKAFTA net pricing in overlapping genotype subgroups?
4. What settlement agreement terms most often determine the first generic or competing product’s effective launch date?
5. How do pediatric label expansions change TRIKAFTA’s incident-start growth and long-term revenue profile?

---

References (APA)

1. Vertex Pharmaceuticals. (n.d.). Company filings and investor presentations.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
3. FDA. (n.d.). Drugs@FDA database for TRIKAFTA approvals and label history.